Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PheoniX is a multi-ingredient dietary supplement marketed primarily as a stimulant-free fat burner. It is designed to support weight loss through several distinct biological pathways without the use of caffeine or other traditional stimulants. The formulation typically includes synephrine, naringin, and hesperidin, which are intended to stimulate the beta-3 adrenergic receptors and increase the basal metabolic rate. Additionally, it contains forskolin, which activates the enzyme adenylyl cyclase, thereby increasing intracellular levels of cyclic adenosine monophosphate (cAMP) to promote lipolysis. Other components like epigallocatechin gallate (EGCG) inhibit catechol-O-methyltransferase (COMT) to prolong the activity of fat-burning hormones, while 5-HTP is included to support serotonin production and potentially reduce appetite. The product is developed and marketed by Legion Athletics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PheoniX.